Health hazard evaluation report: HETA-90-140-2221, George Washington University Medical Center, Washington, D.C.
Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, HETA 90-140-2221, 1992 May; :1-17
Exposure during aerosolized pentamidine administration was investigated in response to concerns raised by a published report about pulmonary diffusing capacity in a health care worker and diagnosis of idiopathic pulmonary fibrosis in a worker administering pentamidine (100334) at the George Washington University Medical Center (SIC-8069) in Washington, DC. Pentamidine has been used in the treatment of protozoal diseases, particularly Pneumocystis- carinii pneumonia, an opportunistic infection in patients with compromised immune function. Environmental measurements indicated a pentamidine concentration of 0.04 micrograms/cubic meter in a personal breathing zone air sample for a nurse involved in administering the medication, and 0.09 and 0.13 micrograms/cubic meter in area air samples outside the treatment room. Of four employees interviewed, two expressed occasional symptoms of mild chest tightness associated with exposure to the medication. The authors conclude that the recognized irritant effects of pentamidine, its potential to cause bronchospasm, and the risk of tuberculosis transmission in these settings justify continued efforts to minimize worker exposure.
NIOSH-Author; NIOSH-Health-Hazard-Evaluation; NIOSH-Technical-Assistance-Report; HETA-90-140-2221; Hazard-Confirmed; Region-3; Health-care-personnel; Pharmaceuticals; Medical-treatment; Occupational-exposure;
Field Studies; Hazard Evaluation and Technical Assistance
NTIS Accession No.
National Institute for Occupational Safety and Health